P1129: Comparison of discontinuation/switching between adalimumab biosimilar and originator in Inflammatory Bowel Disease patients: Preliminary data from CAN-AIMECCO'25Year: 2025
Authors: Lukusa, L.(1);Birck, M.G.(1);Moura, C.S.(1);Neville, A.(1);Zezos, P.(2);Narula, N.(3);Targownik, L.E.(4);Ma, C.(5);Purdy, E.(5);Afif, W.(6)*;Singh, H.(7);Oketola, B.(7);Bernatsky, S.(1);
(1)Research Institute of the McGill University Health Centre, Centre for Outcomes Research and Evaluation, Montreal, Canada;(2)Thunder Bay Health Sciences Centre- Northern Ontario School of Medicine, Division of Gastroenterology- Department of Internal Medicine, Thunder Bay, Canada;(3)McMaster University, Division of Gastroenterology- Department of Medicine- Farncombe Family Digestive Health Research Institute, Hamilton, Canada;(4)Mount Sinai Hospital, Division of Gastroenterology, Toronto, Canada;(5)University of Calgary, Cumming School of Medicine, Calgary, Canada;(6)McGill University, Division of Gastroenterology, Montreal, Canada;(7)University of Manitoba, Max Rady College of Medicine, Winnipeg, Canada;
P1130: Real-life histological remission in Ulcerative Colitis patients treated with Ustekinumab: results from the Belgian SULTAN trialECCO'25Year: 2025
Authors: Holvoet, T.(1)*;Truyens, M.(2);Reenaers, C.(3);Baert, F.(4);Vandenbranden, S.(5);Anneline, C.(6);Pouillon, L.(7);Dewint, P.(8);Van Moerkercke, W.(9);Rahier, J.F.(10);Vandermeulen, L.(11);Van Dongen, J.(12);Peeters, H.(13);Lambrecht, G.(14);Vijverman, A.(15);Hoorens, A.(16);Vanhaecke, A.(16);Lobaton, T.(17);
(1)VITAZ, Gastroenterology, Sint Niklaas, Belgium;(2)Ghent University Hospital, Gastroenterology, Ghent, Belgium;(3)CHU Liege, Gastroenterology, Liege, Belgium;(4)AZ Delta, Gastroenterology, Roeselare, Belgium;(5)OLV Aalst, Gastroenterology, Aalst, Belgium;(6)Erasme, Gastroenterology, Brussels, Belgium;(7)Imelda, Gastroenterology, Bonheiden, Belgium;(8)AZ Maria Middelares, Gastroenterology, Gent, Belgium;(9)AZ Groeninge, Gastroenterology, Kortrijk, Belgium;(10)CHU Namur, Gastroenterology, Namur, Belgium;(11)UZ Brussel, Gastroenterology, Brussel, Belgium;(12)AZ Sint Maarten, Gastroenterology, Mechelen, Belgium;(13)AZ Sint Lucas, Gastroenterology, Gent, Belgium;(14)AZ Damiaan, Gastroenterology, Oostende, Belgium;(15)CHR de la citadelle, Gastroenterology, Liege, Belgium;(16)UZ Gent, Pathology, Gent, Belgium;(17)UZ Gent, Gastroenterology, Gent, Belgium;
1. Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology 2021;160:1570–1583.
P1131: A snapshot of nutritional bloods in newly diagnosed paediatric patients with Crohn’s disease (CD), Ulcerative colitis (UC) and Early Onset IBD (EOIBD) and their follow up post treatment of nutrient deficiency.ECCO'25Year: 2025
Authors: Arpe, L.(1)*;Kiparissi, F.(2);Williamson , A.(2);
(1)Great Ormond Street Hospital, Dietetics, London, United Kingdom;(2)Great Ormond Street Hospital, gastroenterology, London, United Kingdom;
Gerasimidis K;Bronsky J;Catchpole A;Embleton N;Fewtrell M;Hojsak I;Indrio F;Hulst J;Köglmeier J;de Koning B;Lapillonne A;Molgaard C;Moltu SJ;Norsa L;Verduci E;Domellöf M; ; (2020) Assessment and interpretation of Vitamin and trace element status in sick children: A position paper from the European Society for Paediatric Gastroenterology Hepatology, and Nutrition Committee on Nutrition, Journal of pediatric gastroenterology and nutrition. Available at: https://pubmed.ncbi.nlm.nih.gov/32443051/ (Accessed: 26 September 2023)
P1132: Patterns and predictors of steroid use in people with IBD in routine care across ANZECCO'25Year: 2025
Authors: Rivas, C.(1)*;Su, W.K.(1,2,3);Wilson, W.(4);Ng, W.(1,5);Ghaly, S.(6,7);Walker, G.(8,9,10);Forbes, A.(11);Su, H.(12);Schultz, M.(13);Lawrance, I.(14,15);Dutt, S.(16,17);Brett, L.(18);Begun, J.(19,20);Lynch, K.(21,22);Andrews, J.M.(2,22,23);Connor, S.(2,24,25);
(1)Liverpool Hospital- Liverpool, Department of Gastroenterology and Hepatology, Sydney, Australia;(2)Crohn's Colitis Cure, CCCure, Sydney, Australia;(3)The Ingham Institute for Applied Medical Research, Department of Gastroenterology and Hepatology- Liverpool- Australia, Sydney, Australia;(4)Lyell McEwin Hospital- Adelaide- South Australia, Department of Anaesthetics, Adelaide, Australia;(5)University of New South Wales, Department of Medicine & Health- South Western Clinical School, Sydney, Australia;(6)St Vincent's Public Hospital, Department of Gastroenterology, Sydney, Australia;(7)University of New South Wales, St Vincent's Clinical School, Sydney, Australia;(8)Royal Brisbane and Women's Hospital, Department of Gastroenterology and Hepatology, Brisbane, Australia;(9)QIMR Berghofer- Brisbane- Australia, Medical Research, Brisbane, Australia;(10)University of Queensland, Centre for Clinical Research, Brisbane, Australia;(11)University of Otago, Department of Medicine, Christchurch, New Zealand;(12)Te Whatu Ora Health New Zealand Waitaha Canterbury, Department of Gastroenterology, Christchurch, New Zealand;(13)University of Otago, Department of Medicine- Dunedin School of Medicine, Dunedin, New Zealand;(14)Saint John of God Subiaco Hospital- Australia, Centre for Inflammatory Bowel Disease, Perth, Australia;(15)University of Western Australia, School of Medicine and Pharmacology, Murdoch, Australia;(16)Children's Hospital at Westmead Clinical School, Speciality of Child and Adolescent Health, Sydney, Australia;(17)The University of Sydney, School of Medicine- Faculty of Medicine and Health, Sydney, Australia;(18)Logan Hospital, Department of Gastroenterology, Queensland, Australia;(19)Mater Hospital Brisbane, Department of Gastroenterology, Brisbane, Australia;(20)Mater Research, The University of Queensland - Faculty of Medicine, Queensland, Australia;(21)Royal Adelaide Hospital- Australia, Department of Gastroenterology and Hepatology, Adelaide, Australia;(22)University of Adelaide, Faculty of Health Sciences, Adelaide, Australia;(23)Central Adelaide Local Health Network, Department of Gastroenterology, Adelaide, Australia;(24)Liverpool Hospital, Department of Gastroenterology and Hepatology, Sydney, Australia;(25)University of New South Wales, Medicine & Health- South Western Sydney Clinical School-, Sydney, Australia;
P1133: Safety and effectiveness of indigo naturalis for induction of remission in children with mild to moderate ulcerative colitis: a prospective open-label trialECCO'25Year: 2025
Authors: Yogev, D.(1);Weintraub, Y.(2);Ledder, O.(1);Matar, M.(2);Krauthammer, A.(3);Shavit-Brunschwig, Z.(1);Salomon, N.(4);Assa, A.(1);Turner, D.(1);Orlanski-Meyer, E.(1);Shouval, D.(2)*;
(1)Shaare Zedek Medical Center, Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(2)Schneider Children's Medical Center of Israel, Institute of Gastroenterology- Nutrition and Liver Diseases, Petah Tikva, Israel;(3)Edmond and Lily Safra Children's Hospital, Pediatric Gastroenterology and Nutrition Unit, Ramat Gan, Israel;(4)Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;
P1134: The effectiveness of medical therapies for dermatological extraintestinal manifestations in patients with IBD: an umbrella reviewECCO'25Year: 2025
Authors: Noor, N.(1)*;Prabhu, A.(1);Lim, A.(1);Krishnakumar, A.(1);Yuan, Y.(2);Jairath, V.(2);
(1)University of Cambridge School of Clinical Medicine, Department of Medicine, Cambridge, United Kingdom;(2)Western University, Department of Gastroenterology, London, Canada;
P1136: Mesenteric excision and endoscopic recurrence in ileocaecal Crohn's Disease: a single centre experienceECCO'25Year: 2025
Authors: Jones, T.(1)*;Jayasooriya, N.(2);Thoua, N.(2);Ghanbari, A.(1);
(1)Homerton University Hospital, Colorectal surgery, London, United Kingdom;(2)Homerton University Hospital, Gastroenterology, London, United Kingdom;
1. Nardone OM, Calabrese G, Barberio B, et al. Rates of Endoscopic Recurrence In Postoperative Crohn’s Disease Based on Anastomotic Techniques: A Systematic Review And Meta-Analysis. Inflamm Bowel Dis. 2024;30(10):1877–87.
2. Brown SR. How can the surgeon reduce recurrence after surgery for ileocolic Crohn's disease? Semin Colon Rectal Surg. 2023;34(4):100985.
P1137: Prognostic value of intestinal ultrasound (IUS) in patients with Acute Severe Ulcerative colitis (ASUC) – A single center experience.ECCO'25Year: 2025
Authors: Zacharopoulou, E.(1)*;Bellou, G.(1);Palatianou, M.(1);Pagoni, A.(1);Internos, I.(1);Leontidis, N.(1);Neokleous, A.(1);Tribonias, G.(2);Tzouvala, M.(1);
(1)General Hospital of Nikea and Pireaus, Gastroenterology, Athens, Greece;(2)General Hospital of Athens Korgialeneio - Benakeio Hellenic Red Cross, Gastroenterology, Athens, Greece;
1. Ilvemark JFKF, Wilkens R, Thielsen P, et al. Early Intestinal Ultrasound Predicts Intravenous Corticosteroid Response in Hospitalised Patients With Severe Ulcerative Colitis. J Crohns Colitis. 2022;16(11):1725-1734. doi:10.1093/ecco-jcc/jjac083
2. Allocca M, Dell'Avalle C, Craviotto V, et al. Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study. United European Gastroenterol J. 2022;10(2):190-197. doi:10.1002/ueg2.12206
P1138: Curcumin-QingDai combination for patients with active Crohn’s disease: Initial real-world experience from a retrospective multi-center cohort studyECCO'25Year: 2025
Authors: Salomon, N.(1)*;Marom, M.(2);Odeh, S.(3);Molnar, M.(2);Shitrit, A.B.G.(4);Nayshool, O.(5);Ungar, B.(1);Ben-Horin, S.(1);Rainis, T.(2);
(1)Sheba Medical Center, Gastroenterology, Ramat Gan, Israel;(2)Bnai Zion Medical Center, Gastroenterology, Haifa, Israel;(3)Bnai Zion Medical Center, Gastroentrology, Haifa, Israel;(4)Shaarei Zedek Medical center, Gastroenterology, Jerusalem, Israel;(5)Sheba Medical Center, Gastroenterology, Ramat-Gan, Israel;
1. Yanai H, Salomon N, Lahat A, Ungar B, Eliakim R, Kriger-Sharabi O, Reiss-Mintz H, Koslowsky B, Shitrit AB, Tamir-Degabli N, Dotan I, Zittan E, Maharshak N, Hirsch A, Ben-Horin S, Kopylov U. Real-world experience with Curcumin-QingDai combination for patients with active ulcerative colitis: A retrospective multicentre cohort study. Aliment Pharmacol Ther. 2023 Jul;58(2):175-181
2. Ben-Horin S, Salomon N, Karampekos G, Viazis N, Lahat A, Ungar B, Eliakim R, Kuperstein R, Kriger-Sharabi O, Reiss-Mintz H, Yanai H, Dotan I, Zittan E, Maharshak N, Hirsch A, Weitman M, Mantzaris GJ, Kopylov U. Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial. Clin Gastroenterol Hepatol. 2024 Feb;22(2):347-356
P1140: Filgotinib effectiveness and safety in moderate and severely active patients with Ulcerative Colitis: early real-world outcomes in an interim analysis of data from the prospective, observational GALOCEAN studyECCO'25Year: 2025
Authors: Seenan, J.P.(1)*;Høivik, M.L.(2,3);Vermeire, S.(4);Schreiber, S.(5);Reinisch, W.(6);Löwenberg, M.(7);Doherty, G.(8);Gilletta de Saint Joseph, C.(9);Ricart, E.(10,11);Saldaña, R.(12);Sawyer, W.(13);Bouzid, O.(14);Rudolph, C.(15);Armuzzi, A.(16,17);
(1)Queen Elizabeth University Hospital, Gastroenterology, Glasgow, United Kingdom;(2)Oslo University Hospital, Department of Gastroenterology, Oslo, Norway;(3)University of Oslo, Institute of Clinical Medicine, Oslo, Norway;(4)UZ Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)Kiel University- University Hospital Schleswig-Holstein, Department of Internal Medicine I, Kiel, Germany;(6)Medical University of Vienna, Division of Gastroenterology and Hepatology, Vienna, Austria;(7)Amsterdam UMC- University of Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(8)St Vincent’s University Hospital and School of Medicine- University College Dublin, Centre for Colorectal Disease, Dublin, Ireland;(9)Centre Hospitalier Universitaire de Toulouse, Gastroenterology and Pancreatology Department, Toulouse, France;(10)Hospital Clínic- Institut d'Investigacions Biomèdiques August Pi i Sunyer IDIBAPS, Gastroenterology Department, Barcelona, Spain;(11)Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology Department, Madrid, Spain;(12)European Federation of Crohn's and Colitis Associations EFCCA, Innovation and Patient Engagement, Brussels, Belgium;(13)Alfasigma S.p.A., Biostatistics, Bologna, Italy;(14)Alfasigma S.p.A., Evidence Generation- Global Medical Affairs, Bologna, Italy;(15)Alfasigma S.p.A., Medical Director Gastroenterology- Specialty Care- Global Medical Affairs, Bologna, Italy;(16)IRCCS Humanitas Research Hospital- Rozzano, Inflammatory Bowel Disease Center, Milan, Italy;(17)Humanitas University- Pieve Emanuele, Department of Biomedical Sciences, Milan, Italy;
1. Schreiber S et al. United European Gastroenterol J. Forthcoming 2024.
P1141: Guselkumab efficacy and safety in East Asian participants with moderate to severely active Ulcerative Colitis: Subgroup analysis of the Phase 2b/3 QUASAR induction and maintenance studiesECCO'25Year: 2025
Authors: Chen, B.(1);Ye, B.D.(2);Cao, Q.(3);Hirai, F.(4);Saruta, M.(5);Chen, M.(6);Pelak, S.(7);Shipitofsky, N.(7);Wahking, B.(8);Zhuo, J.(9);Hisamatsu, T.(10)*;
(1)The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China;(2)University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea- Republic Of;(3)Sir Run Run Shaw Hospital- Zhejiang University, School of Medicine, Hangzhou, China;(4)Fukuoka University Hospital, Department of Gastroenterology and Medicine, Fukuoka, Japan;(5)The Jikei University School of Medicine, Department of Internal Medicine, Tokyo, Japan;(6)Sun Yat-sen University, The First Affiliated Hospital, Guangzhou, China;(7)Janssen Research & Development- LLC, Immunology, Spring House, United States;(8)Janssen Asia Pacific, Medical Affairs, Singapore, Singapore;(9)Janssen China R&D, Statistics, Shanghai, China;(10)Kyorin University, School of Medicine, Tokyo, Japan;
1. Peyrin-Biroulet L, Allegretti JR, Rubin DT, et al. Gastroenterology. 2023;165(6):1443-1457.
2. Allegretti JR, Peyrin-Biroulet L, Feagan BG, et al. Gastroenterology. 2023;164(6):S-1572.
3. Rubin DT, Allegretti JR, Panés J, et al. Gastroenterology. 2024;166(5 Suppl.): S-180.
P1142: Time to clinical recapture after dose escalation of subcutaneous infliximab (CT-P13 SC) following loss of response: A post hoc analysis of the 2-year Phase 3 LIBERTY-CD & LIBERTY-UC trialsECCO'25Year: 2025
Authors: Dubinsky, M.C.(1)*;Schreiber, S.(2);Yarur, A.J.(3);Sands, B.E.(4);Hanauer, S.B.(5);Danese, S.(6);Yu, H.(7);Kim, D.H.(7);Lee, Y.N.(7);Colombel, J.F.(4);
(1)Icahn School of Medicine at Mount Sinai, Department of Pediatrics- Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, New York NY, United States;(2)University Hospital Schleswig-Holstein, Department of Medicine I, Kiel, Germany;(3)Cedars Sinai Medical Center, F. Widjaja Inflammatory Bowel Disease Institute, Los Angeles, United States;(4)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York NY, United States;(5)Northwestern University- Feinberg School of Medicine, Division of Gastroenterology and Hepatology- Department of Medicine, Chicago IL, United States;(6)IRCCS San Raffaele Hospital and Vita-Salute University, Department of Gastroenterology, Milan, Italy;(7)Celltrion- Inc., Global Medical Division, Incheon, Korea- Republic Of;
1. European Medicines Agency. Available at: https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf. Accessed November 18, 2024.
2. Hanauer SB, et al. Gastroenterology. 2024;167(5):919-933.
3. Danese S, et al. Gastroenterology. 2024;166(3):S13.
P1143: Impact of vitamin D metabolism gene polymorphisms on therapeutic efficacy of vedolizumab and ustekinumab in Inflammatory Bowel Disease.ECCO'25Year: 2025
Authors: De Vita, F.(1)*;Ribaldone, G.R.(1);D'Avolio, A.(1);Infusino, V.(1);Antonucci, M.(1);Caviglia, G.P.(1);Armandi, A.(1);Ceccarelli, L.(2);Costa, F.(2);Bottari, A.(2);Fe, P.(2);Bertani, L.(1);Cusato, J.(1);
(1)University of turin, Medical Sciences, Turin, Italy;(2)Pisa University Hospital, General Surgery and Gastroenterology, Pisa, Italy;
1. Trefilio LM, Bottino L, de Carvalho Cardoso R, Montes GC, Fontes-Dantas FL. The impact of genetic variants related to vitamin D and autoimmunity: a systematic review. Heliyon. 2024;10(7). doi:10.1016/j.heliyon.2024.e27700.
2. Cusato J, Bertani L, Antonucci M, et al. Vitamin D-related genetics as predictive biomarker of clinical remission in adalimumab-treated patients affected by Crohn's disease: a pilot study. Pharmaceuticals. 2021;14(12):1230. doi:10.3390/ph14121230.
3. Bertani L, Blandizzi C, Mumolo MG, et al. Fecal calprotectin predicts mucosal healing in patients with ulcerative colitis treated with biological therapies: a prospective study. Clin Transl Gastroenterol. 2020;11(5). doi:10.14309/ctg.0000000000000174.
P1144: Effect of baseline disease severity on achieving efficacy endpoints in patients with Ulcerative Colitis treated with filgotinibECCO'25Year: 2025
Authors: Allez, M.(1)*;Burisch, J.(2,3);Verstockt, B.(4,5);Dignass, A.(6);Fiorino, G.(7);Zabana, Y.(8,9);Saruta, M.(10);Sawyer, W.(11);Rudolph, C.(12);Vyncke, V.(13);Irving, P.(14,15);
(1)Hospital Saint-Louis- AP-HP- Université Paris Cité, Department of Gastroenterology, Paris, France;(2)Copenhagen University Hospital Hvidovre, Gastrounit, Hvidovre, Denmark;(3)Copenhagen University Hospital – Amager and Hvidovre, Copenhagen Center for Inflammatory Bowel Disease in Children- Adolescents and Adults-, Hvidovre, Denmark;(4)University Hospitals Leuven- KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(5)KU Leuven, Department of Chronic Disease and Metabolism, Leuven, Belgium;(6)Agaplesion Markus Hospital- Goethe University, Department of Medicine I, Frankfurt/Main, Germany;(7)San Camillo-Forlanini Hospital, IBD Clinical Trial Unit, Rome, Italy;(8)MútuaTerrassa University Hospital, Inflammatory Bowel Diseases Unit- Gastroenterology Department, Barcelona, Spain;(9)Biomedical Research Center on Liver and Digestive Diseases CIBEREHD, Inflammatory Bowel Diseases Unit, Madrid, Spain;(10)The Jikei University School of Medicine, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Tokyo, Japan;(11)Alfasigma S.p.A., Biostatistics, Bologna, Italy;(12)Alfasigma S.p.A., Medical Director Gastroenterology- Specialty Care- Global Medical Affairs, Bologna, Italy;(13)Alfasigma S.p.A., Medical Established Rx TA/CHC- Global Medical Affairs, Bologna, Italy;(14)Guy's and St. Thomas' NHS Foundation Trust- London- UK, Department of Gastroenterology, London, United Kingdom;(15)School of Immunology and Microbial Sciences, King’s College London, London, United Kingdom;
1. Löwenberg M et al.United European Gastroenterol J 2024;12 Suppl 2:406–7.
2. Schreiber S et al.United European Gastroenterol J 2024; doi:10.1002/ueg2.12686.
3. Feagan BG et al. Lancet 2021;397:2372–84.
P1145: Comparison of Clinical Relapse between Tofacitinib and Filgotinib as Maintenance Therapy in Ulcerative Colitis Patients in Clinical Remission: A Retrospective Propensity Score-Matched Cohort StudyECCO'25Year: 2025
Authors: Yagi, S.(1)*;Fukui, H.(1);Ikenouchi, M.(1);Shiraishi, T.(1);Wakita, M.(1);Takagi, Y.(1);Sato, T.(1);Kawai, M.(1);Kamikozuru, K.(1);Yokoyama, Y.(1);Takagawa, T.(2);Shinzaki, S.(1);
(1)Hyogo Medical University, Department of Gastroenterology- Faculty of Medicine, Nishinomiya, Japan;(2)Hyogo Medical University, Center for Clinical Research and Education, Nishinomiya, Japan;
P1146: Robotic approach to ileocolic Crohn disease surgery: does it increase the risk of intraoperative incidents compared to laparoscopy? Results of a comparative propensity matched multicentre cohort studyECCO'25Year: 2025
Authors: Husson , T.(1);Abdalla , S.(1);Duval , Q.(2);Zerbib , P.(3);Penna , C.(1);Benoist , S.(1);Cotte , E.(2);Brouquet , A.(1)*;
(1)Hôpital Bicêtre APHP, Digestive and Oncologic Surgery, Le Kremlin Bicêtre, France;(2)Hôpital Lyon Sud, Digestive and Oncologic Surgery, Lyon, France;(3)CHRU Lille, Digestive and Oncologic Surgery, Lille, France;
(1) Calini, Giacomo et al. "Ileocolic resection for Crohn's disease: robotic intracorporeal compared to laparoscopic extracorporeal anastomosis." Journal of robotic surgery vol. 17,5 (2023): 2157-2166. doi:10.1007/s11701-023-01635-6
(2) Abdalla, Solafah et al. "Perioperative outcomes of minimally invasive ileocolic resection for complicated Crohn disease: Results from a referral center retrospective cohort." Surgery vol. 172,2 (2022): 522-529. doi:10.1016/j.surg.2022.01.046
P1147: Proactive therapeutic drug monitoring of infliximab leads to durability of treatment in children with Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Chuah, C.W.(1)*;Eldredge, J.(1);Magoffin, A.(1);O'Loughlin, E.V.(1);Park, C.J.(2);Puppi, J.(1);Siew, S.(1,3);Stormon, M.(1);Thacker, K.(1);Dutt, S.(1,3);
(1)The Children's Hospital at Westmead, Department of Gastroenterology, Westmead, Australia;(2)Australian National University, Sydney Adventist Hospital Clinical School- School of Medicine and Psychology, Canberra, Australia;(3)University of Sydney, Children's Hospital Westmead Clinical School- Sydney School of Medicine, Sydney, Australia;
1. Ding, N. S., Hart, A., & De Cruz, P. (2016). Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management. Alimentary pharmacology & therapeutics, 43(1), 30–51. https://doi.org/10.1111/apt.13445
2 Vahabnezhad, E., Rabizadeh, S., & Dubinsky, M. C. (2014). A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease. Inflammatory bowel diseases, 20(4), 606–613. https://doi.org/10.1097/MIB.0000000000000003
P1148: The incidence and predictive factors of thromboembolism during hospitalizations for IBD flare-ups: A retrospective cohort study in Taiwan.ECCO'25Year: 2025
Authors: Meng, M.J.(1)*;Le, P.H.(1,2,3,4);Chung, C.S.(5);Chang, C.W.(6);Pan, Y.B.(7);Kuo, C.J.(1,2,3,4);Chiu, C.T.(1,2,3,4);
(1)Chang Gung Memorial Hospital- Linkou Branch- Taoyuan- Taiwan, Department of Gastroenterology and Hepatology, Taoyuan, Taiwan;(2)Chang Gung Memorial Hospital- Linkou Branch- Taoyuan- Taiwan, Inflammatory Bowel Disease Center, Taoyuan, Taiwan;(3)Chang Gung Memorial Hospital- Linkou Branch- Taoyuan- Taiwan, Microbiota Therapy Center, Taoyuan, Taiwan;(4)Taiwan Association of the Study of Intestinal Disease TASID, Department of Gastroenterology and Hepatology, Taoyuan, Taiwan;(5)Far Eastern Memorial Hospital- New Taipei City- Taiwan, Division of Gastroenterology and Hepatology- Department of Internal Medicine, New Taipei City, Taiwan;(6)MacKay Memorial Hospital- Taipei- Taiwan, Division of Gastroenterology- Department of Internal Medicine, Taipei, Taiwan;(7)Chang Gung Memorial Hospital- Linkou Branch- Taoyuan- Taiwan, Biostatistical Section- Clinical Trial Center, Taoyuan, Taiwan;
